Eastern Health Newfoundland and Labrador
Welcome,         Profile    Billing    Logout  
 2 Trials 
11 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Daley, Peter
PETERPEN, NCT03671967: PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae

Recruiting
4
1084
Canada, RoW
Piperacillin/tazobactam, Meropenem
Rambam Health Care Campus, Rabin Medical Center, University of Modena and Reggio Emilia, Tel Aviv Medical Center, Meir Medical Center, Soroka University Medical Center, The Chaim Sheba Medical Center, McGill University Health Centre/Research Institute of the McGill University Health Centre, Jewish General Hospital, Canadian Institutes of Health Research (CIHR), Hadassah Medical Organization
Beta Lactam Resistant Bacterial Infection, Enterobacteriaceae Infections, Bacteremia
01/26
04/26
SNAP, NCT05137119: Staphylococcus Aureus Network Adaptive Platform Trial

Recruiting
4
8000
Europe, Canada, RoW
Cefazolin, Penicillin, Benzylpenicillin, Penicillin G, Clindamycin, Lincomycin, Vancomycin, Daptomycin, Effectiveness of early switch to oral antibiotics, Whole body FDG PET/CT Imaging
University of Melbourne, Berry Consultants, McGill University Health Centre/Research Institute of the McGill University Health Centre, Menzies School of Health Research, Aotearoa Clinical Trials, Queensland University of Technology, Sunnybrook Health Sciences Centre, Tan Tock Seng Hospital, Telethon Kids Institute, The Peter Doherty Institute for Infection and Immunity, The University of Queensland, UMC Utrecht, Radboud University Medical Center, King's College London, Rambam Health Care Campus, University College, London, Houston Medical Research Institute
Staphylococcus Aureus Bacteremia
12/28
12/28
TAPER-V, NCT04138706: Initial Vancomycin Taper for the Prevention of Recurrent Clostridium Difficile Infection

Active, not recruiting
3
263
Canada
Vancomycin, Placebos
McGill University Health Centre/Research Institute of the McGill University Health Centre, Canadian Institutes of Health Research (CIHR)
Clostridium Difficile Infection
10/24
10/24
CanTreatCOVID, NCT05614349: Canadian Adaptive Platform Trial of Treatments for COVID-19 in Community Settings

Recruiting
3
12000
Canada
Paxlovid, Other
Unity Health Toronto, Canadian Institutes of Health Research (CIHR), Health Canada
COVID-19
01/24
01/25
CATCO, NCT04330690: Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial

Active, not recruiting
3
2900
Canada
Artesunate, Imatinib, Infliximab, Dexamethasone, LSALT Peptide
Sunnybrook Health Sciences Centre, AbbVie, Apotex Inc., World Health Organization, University of British Columbia, Arch Biopartners Inc.
COVID-19
03/24
05/24
ATTACC-CAP, NCT05848713: AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia

Recruiting
3
4000
Canada, US, RoW
Heparin
University of Manitoba, Canadian Institutes of Health Research (CIHR), Research Manitoba, Ozmosis Research Inc., Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network, Canadian Critical Care Trials Group, AVANTI
Community-acquired Pneumonia
03/28
03/29
NCT03988855: An Exploratory, Open-Label, Oligo-Center Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravenous DNV3837 in Subjects With Clostridium Difficile Infection

Recruiting
2
40
Canada, US
DNV3837
Deinove
Clostridium Difficile (C. Difficile)
12/22
12/22
BALANCE, NCT03005145: Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness

Completed
N/A
3622
Europe, Canada, US, RoW
7 days of adequate antibiotic treatment, 14 days of adequate antibiotic treatment.
Sunnybrook Health Sciences Centre
Bacteremia, Intensive Care, Critically Ill, Sepsis, Mortality, Antimicrobial
05/23
08/23
NCT06537609: A Platform Trial for Gram Negative Bloodstream Infections

Recruiting
N/A
2500
Canada
De-escalation VS No De-escalation, Oral beta-lactams VS non beta-lactams, Central vascular catheter retention VS Central vascular catheter replacement, Cephalosporin VS Carbapenem for low risk AmpC organisms, Routine follow-up blood culture VS No routine follow-up blood culture
Sunnybrook Health Sciences Centre, Canadian Institutes of Health Research (CIHR)
Gram-negative Bacteremia
04/27
04/28
BALANCE+, NCT05893147: Vanguard Phase

Completed
N/A
174
Canada
De-escalation VS No De-escalation, Oral beta-lactams VS non beta-lactams, Central vascular catheter retention VS Central vascular catheter replacement, Cephalosporin VS Carbapenem for low risk AmpC organisms, Routine follow-up blood culture VS No routine follow-up blood culture
Sunnybrook Health Sciences Centre, Canadian Institutes of Health Research (CIHR)
Gram-negative Bacteremia
07/24
08/24
Kuff, Krista
CanTreatCOVID, NCT05614349: Canadian Adaptive Platform Trial of Treatments for COVID-19 in Community Settings

Recruiting
3
12000
Canada
Paxlovid, Other
Unity Health Toronto, Canadian Institutes of Health Research (CIHR), Health Canada
COVID-19
01/24
01/25

Download Options